Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Aug;34(8):e363-e364.
doi: 10.1111/jdv.16590. Epub 2020 Jun 4.

Improvement of SARS-CoV-2 symptoms following Guselkumab injection in a psoriatic patient

F Benhadou  1 , V Del Marmol  1
Affiliations
Case Reports

Improvement of SARS-CoV-2 symptoms following Guselkumab injection in a psoriatic patient

F Benhadou et al. J Eur Acad Dermatol Venereol. 2020 Aug.
No abstract available

PubMed Disclaimer

References

    1. Messina F, Piaserico S. SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐23 inhibitor. J Eur Acad Dermatol Venereol 2020. 10.1111/jdv.16468 - DOI - PMC - PubMed
    1. Blauvelt A, Gooderham M, Iversen L et al. Efficacy and safety of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER‐3). J Am Acad Dermatol 2017; 77: 855–862. - PubMed
    1. Vaninov N. In the eye of the COVID‐19 cytokine storm. Nat Rev Immunol 2020; 20: 277–277. - PMC - PubMed
    1. Mehta P, McAuley DF, Brown M et al. COVID‐19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033–1034. - PMC - PubMed
    1. Blauvelt A, Papp KA, Griffiths CE et al. Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double‐blinded, placebo‐ and active comparator‐controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76: 405–417. - PubMed